A constrained funding environment and weaker Euro negatively impacted Affymetrix's gene expression array and eBioscience business units in the third quarter, causing the firm to report lower-than-expected preliminary revenues and eliciting concern from analysts and investors alike.

The Santa Clara, Calif.-based life sciences company this week said that it expects total revenue of approximately $80 million for the three months ended Sept. 30, missing an average consensus analyst expectation of $84.6 million.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

New Mexico is re-doing its proposed science education standards after criticism, the Associated Press reports.

Agbio executives say gene editing will speed up breeding efforts, according to the Wall Street Journal.

La Trobe University's Jenny Graves has won the $250,000 Prime Minister's Prize for Science, the Guardian reports.

In Cell this week: post-treatment changes to melanoma genome, multi-omics analysis of muscle-invasive bladder cancer, and more.